After seeing success with a “buy” rating, Needham shifted Medtronic to “strong buy.” The company’s stock now sits at $119 per share, a 31 percent uptick from $103.
Needham attributed the upgrade to the company’s “strong product cycle, valuation and potential to beat [full-year 2019] consensus,” according to Seeking Alpha.
On the other end, Zimmer Biomet’s stock was downgraded from “strong buy” to “buy.” The company’s stock is now $150 per share. Needham attributed the lack in orthopedic growth and portfolio management to Zimmer Biomet’s downgrade.
More articles on devices and implants:
28 spine devices receive FDA 510(k) clearance in July
Smith & Nephew stock sees downgrade over surgical robots market concerns
3 things to know about the global interbody fusion cage market
